International infant formula manufacturers are adjusting their business practices in China having been found guilty of price fixing. Multina...
There were, despite continued economic uncertainty in many Western markets and concerns over slowing growth in the East, signs that M&A acti...
Nestle's health science division has continued to motor below the radar in the first half of 2012 and the group is confident of a bright fut...
Nestle has said innovation is key to growth in developed markets where the company says achieving higher sales is "no walk in the park"....
Nestle is witnessing dynamic growth in China thanks to a combination of M&A and organic growth. As we discovered in part one of this two part interview, regional chief Roland Decorvet attributes much of this success to Nestle's use of local and global brands. But operating in China is not without its challenges. Katy Askew caught up with Decorvet to find out more about why he believes Nestle is best-placed of all the multinationals to succeed in China.
The potential offered by the Chinese market is nothing new. And nor is Nestle's presence in the country. The world's largest food group started trading in Hong Kong in 1874 and opened its first sales office on the mainland in 1908. In recent years Nestle has stepped up the pace with the development of a distinctive model it believes will drive expansion. In part one of the just-food interview, Roland Decorvet, chairman and CEO of Nestle Greater China, spoke to Katy Askew about the company's strategy in the market.
South African pharma group Aspen Holdings has snapped up 50% of New Zealand infant formula producer New Zealand New Milk.
Nestle has sold baby food brands Alete and Milasan to German investment firm BWK for an undisclosed sum.
South African pharmaceutical group Aspen Pharmacare has acquired Nestle's infant milk factory in Mexico and licences for some of its brands in Latin America.
Aspen Pharmacare is to acquire the Pfizer infant nutrition businesses in Australia and southern Africa after a deal with Nestle worth US$215m.
Nestle will sell Pfizer's Mexican business to settle competition issues in the market arising from its deal last year to buy the pharmaceutical giant's infant nutrition operations worldwide.
- Deal or no deal: Frozen sale makes sense for Kerry
- On the money: How Greencore is outperforming
- Comment: Mondelez digital strategy suffers blow
- Shopper trends: Promos can mean higher prices
- JBS sees big opportunity from Primo Smallgoods
- Kerry puts frozen food unit on block - reports
- Coca-Cola eyes long-term rewards with dairy push
- Post issues warning over US cereal sector sales
- UPDATE: Greencore eyes US$1bn US business
- Danone "mulls Yakult stake sale"